Evidence map›Paper›PMID 33069067›Full record

ArticleBioorganic & medicinal chemistry2020

Rational design of cell-permeable cyclic peptides containing a d-Pro-l-Pro motif.

Jin Wen, Hui Liao, Kye Stachowski, Jordan P Hempfling, Ziqing Qian, Chunhua Yuan, Mark P Foster, Dehua Pei

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. β-Hairpin Peptidomimetics for Protein-Protein Interaction Inhibition.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Review
  4. Designing Cell-Permeable Peptide Therapeutics That Enter the Cell by Endocytosis.ACS symposium series. American Chemical Society · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jin WenDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA.
Hui LiaoDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA.
Kye StachowskiDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA.
Jordan P HempflingDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA.
Ziqing QianDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA.
Chunhua YuanCampus Chemical Instrument Center, The Ohio State University, 460 West 12(th) Avenue, Columbus, OH 43210, USA.
Mark P FosterDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA. Electronic address: foster.281@osu.edu.
Dehua PeiDepartment of Chemistry and Biochemistry and Ohio State Biochemistry Program, The Ohio State University, 484 West 12(th) Avenue, Columbus, OH 43210, USA. Electronic address: pei.3@osu.edu.

Funding

Development of Cell-Permeable Peptides and ProteinsR35GM122459 · NIGMS · OHIO STATE UNIVERSITY · PI Dehua Pei · 2017 to 2026
$5.1M
Macrocyclic Peptidyl Inhibitors of NEMO-IKK InteractionR01CA234124 · NCI · OHIO STATE UNIVERSITY · PI PEI, DEHUA, WANG, QIEN · 2019 to 2023
$2.1M
Protein Dynamics in Site-Specific DNA RecombinationR01GM122432 · NIGMS · OHIO STATE UNIVERSITY · PI FOSTER, MARK P. · 2017 to 2020
$1.1M
Brd4 interactions with host and viral proteins via the extra-terminal domainR21AI124463 · NIAID · OHIO STATE UNIVERSITY · PI FOSTER, MARK P. · 2016 to 2017
$415k
NCI NIH HHS R01 CA234124NIAID NIH HHS R21 AI124463NIGMS NIH HHS R01 GM122432NIGMS NIH HHS R35 GM122459
6 · The paper itself

Abstract

Cyclic peptides are capable of binding to challenging targets (e.g., proteins involved in protein-protein interactions) with high affinity and specificity, but generally cannot gain access to intracellular targets because of poor membrane permeability. In this work, we discovered a conformationally constrained cyclic cell-penetrating peptide (CPP) containing a d-Pro-l-Pro motif, cyclo(AFΦrpPRRFQ) (where Φ is l-naphthylalanine, r is d-arginine, and p is d-proline). The structural constraints provided by cyclization and the d-Pro-l-Pro motif permitted the rational design of cell-permeable cyclic peptides of large ring sizes (up to 16 amino acids). This strategy was applied to design a potent, cell-permeable, and biologically active cyclic peptidyl inhibitor, cyclo(Y

Indexed as

Drug DesignCell-Penetrating PeptidesDipeptidesDose-Response Relationship, DrugGRB2 Adaptor ProteinHumansMolecular StructurePeptides, Cyclicsrc Homology DomainsStructure-Activity RelationshipTumor Cells, CulturedCell-Penetrating PeptidesDipeptidesGRB2 Adaptor ProteinGRB2 protein, humanPeptides, Cyclicprolyl-prolineCell-penetrating peptideCyclic peptideGrb2 SH2 domainProtein-protein interactionβ-Hairpin

Identifiers

PMID33069067
PMCPMC7577319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.